Lipocine Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, reporting a third-quarter net loss of $666,192 and total revenues of $2,290,072, driven by a $2,100,000 license revenue recognition.

Key Highlights

  • Q3 2026 net loss: $666,192, compared to $3,186,832 in Q3 2025, according to the filing.
  • Q3 2026 total revenues: $2,290,072, versus $114,574 in Q3 2025, with $2,100,000 attributed to license revenue.
  • Nine-month net loss: $6,960,681 for the nine months ended September 30, 2026, compared to $7,257,421 for the same period in 2025.
  • Cash and marketable securities: Cash and cash equivalents stood at $2,594,151, with marketable investment securities of $18,861,297 as of September 30, 2026.
  • Accumulated deficit: $216,357,048 as of September 30, 2026, up from $209,396,367 at December 31, 2025.
  • Shares outstanding: 11,073,439 shares of common stock as of November 4, 2026.
  • Total stockholders' equity: $21,162,148 as of September 30, 2026, compared to $14,477,416 at December 31, 2025.

Lipocine's Q3 2026 Financial Results: License Revenue Drives Sharp Reduction in Quarterly Loss

According to the filing, Lipocine Inc. (NASDAQ:LPCN) reported total revenues of $2,290,072 for the three months ended September 30, 2026, a substantial increase from $114,574 in the same quarter of 2025. The company disclosed that $2,100,000 of Q3 2026 revenue came from license revenue, with royalty revenue contributing an additional $190,072. For the nine-month period, total revenues reached $2,599,568, compared to $831,287 in the first nine months of 2025.

The filing reported total operating expenses of $3,158,597 for Q3 2026, down from $3,475,614 in Q3 2025. Research and development expenses were $2,070,033 for the quarter, compared to $2,707,777 in Q3 2025, while general and administrative expenses were $1,088,564 versus $767,837 in the prior-year quarter. The resulting operating loss for Q3 2026 was $868,525, narrowing significantly from $3,361,040 in Q3 2025. After other income of $202,333 from interest and investment income, the net loss attributable to common shareholders was $666,192, or $(0.08) per basic and diluted share, compared to $(0.59) per share in Q3 2025.

On the balance sheet, the company disclosed total assets of $23,196,594 as of September 30, 2026, up from $17,005,612 at December 31, 2025. The increase in total assets was driven largely by growth in marketable investment securities, which rose to $18,861,297 from $9,724,545 at year-end 2025. Total liabilities decreased to $2,034,446 from $2,528,196 over the same period. The filing shows that during the nine months ended September 30, 2026, additional common stock was issued, with shares issued rising from 6,158,779 at December 31, 2025 to 8,245,798 at September 30, 2026, and stock-based compensation contributed to additional paid-in capital.

What Was Disclosed

Lipocine filed its Form 10-Q for Q3 2026, disclosing a narrowed quarterly net loss of $666,192, revenues of $2,290,072 anchored by a $2,100,000 license fee, total assets of $23,196,594, and an accumulated deficit of $216,357,048 as of September 30, 2026.